GlassScriptPhysician profile
Karolinne M Rocha
NPI 1699098053
$552,032.19
in general payments reported to CMS, 2019-2025
27 companies · $63K in 2025
The $63K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133K · 2020: $85K · 2021: $92K · 2022: $72K · 2023: $28K · 2024: $79K · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $149K · Food and Beverage: $10K · Travel and Lodging: $6,058 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,875 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $148,840.00 |
| Food and Beverage | $10,384.93 |
| Travel and Lodging | $6,058.09 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,875.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $262.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $299,159.58 | 2019-2025 | Compact Intuitiv, Ifs Advanced Femtosec Laser, Tecnis Iol |
| Bausch & Lomb Americas INC. | $66,209.79 | 2022-2025 | Stellaris Elite, Envista Mx60 Iol, Envista Aspire Iol |
| Allergan, INC. | $59,195.29 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $53,857.49 | 2019-2021 | |
| Alcon Vision LLC | $16,243.28 | 2019-2025 | Tryptyr, Clareon, Acrysof Iq Panoptix Uv Iol |
| Abbvie INC. | $14,689.54 | 2021-2025 | Vuity, Alphagan P, Lumigan |
| Dompe US, INC. | $14,604.44 | 2019-2024 | Oxervate |
| Rayner Intraocular Lenses Limited | $5,330.64 | 2023-2024 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Tarsus Pharmaceuticals, INC. | $4,774.04 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $2,497.64 | 2019-2023 | |
| Carl Zeiss Meditec, INC. | $2,455.84 | 2019-2025 | Iolmaster 700, Mel 90, Cirrus Hd-Oct |
| Alcon Research LLC | $2,160.94 | 2019-2025 | |
| Oculus, INC. | $1,500.00 | 2019 | |
| Glaukos Corporation | $1,495.68 | 2023-2025 | Kxl System, Photrexa Viscous and Photrexa |
| Omeros Corporation | $1,442.81 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,257.30 | 2019-2025 | Cequa |
| Hoya Surgical Optics, INC | $1,250.00 | 2024 | |
| Kala Pharmaceuticals, INC. | $1,250.00 | 2021 | |
| Lensar, INC. | $700.00 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $696.59 | 2022-2023 | Tecnis Simplicity, Acuvue |
| Carl Zeiss Meditec USA, INC. | $371.88 | 2022-2023 | Iolmaster 700, Quatera 700 |
| Harrow Eye, LLC | $367.29 | 2025 | Vevye |
| Biotissue Holdings INC. | $247.59 | 2020-2025 | |
| Ocular Therapeutix, INC. | $105.04 | 2019 | |
| Recordati_rare_diseases_inc. | $88.80 | 2023 | Cystadrops, Carbaglu, Cystadane |
| Shire North American Group INC | $80.70 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karolinne Rocha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.